Products
Paritaprevir was approved in many countries in 2014 in film-coated tablet form (Viekirax, combination drug).
Effects
Paritaprevir has antiviral properties against HCV. The effects are due to binding to the NS3/4A protease complex. HCV NS3 serine protease is an enzyme involved in viral replication. To increase availability and allow once-daily administration, paritaprevir is combined with the CYP inhibitor ritonavir.
Indications
For the treatment of chronic hepatitis C (combination therapy).
